Zobrazeno 1 - 5
of 5
pro vyhledávání: '"L K, Hulst"'
Publikováno v:
International journal of clinical pharmacology and therapeutics. 32(5)
Multiple dose pharmacokinetics and tolerability of tirilazad mesylate were assessed at the maximum dosage and duration expected for tirilazad mesylate therapy of subarachnoid hemorrhage and head injury. Healthy male subjects (47) received either 1 mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98066dd5e9e7987815d455f9005e8a80
https://pubmed.ncbi.nlm.nih.gov/7921515
https://pubmed.ncbi.nlm.nih.gov/7921515
Publikováno v:
Pharmaceutical research. 11(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::319750b1e70676599b3d0851b9ab3dd9
https://pubmed.ncbi.nlm.nih.gov/8165199
https://pubmed.ncbi.nlm.nih.gov/8165199
Autor:
Joseph C. Fleishaker, L. K. Hulst
Publikováno v:
European Journal of Clinical Pharmacology. 46
We have assessed the pharmacokinetic and pharmacodynamic interaction between fluvoxamine, a serotonin reuptake inhibitor, and alprazolam, a triazolobenzo-diazepine. Healthy men took fluvoxamine maleate daily for 10 days (50 mg on days 1-3, 100 mg on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4470aadf2b70e67c749f3d515cf4bc21
https://doi.org/10.1007/bf00195913
https://doi.org/10.1007/bf00195913
Publikováno v:
Journal of clinical psychopharmacology. 12(6)
The pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam were studied in 18 young subjects, from 21 to 36 years of age, and 18 elderly subjects, ranging in age from 65 to 76 years. Nine men and 9 women per age group were stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4eee16c19fb23b9fb66bfd48665bac75
https://pubmed.ncbi.nlm.nih.gov/1474178
https://pubmed.ncbi.nlm.nih.gov/1474178
Publikováno v:
European journal of clinical pharmacology. 42(3)
The tolerability, pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam (NDMAD) were assessed following intravenous infusions of 5, 10, 15, and 20 mg adinazolam mesylate, 10, 20, 30 and 40 mg NDMAD mesylate, and placebo. Six s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c86e4cc91fff460521c3177e44a56bf1
https://pubmed.ncbi.nlm.nih.gov/1577047
https://pubmed.ncbi.nlm.nih.gov/1577047